12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Copaxone glatiramer acetate: Development discontinued

Teva announced during an investor meeting on Dec. 11 that it discontinued development of 20 mg/0.5 mL daily Copaxone. The biotech said the program was in Phase III development. Teva also discontinued 11 other programs and said it was discontinuing...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >